AI takes on liver cancer: personalized plan aims to stop return
NCT ID NCT07282184
First seen Dec 16, 2025 · Last updated May 08, 2026 · Updated 20 times
Summary
This study is for people with early-stage liver cancer who are scheduled for surgery. Researchers are testing whether an artificial intelligence (AI) tool can predict each person's risk of the cancer returning. For those at high risk, the study offers a personalized treatment plan that includes medication before and after surgery. The goal is to see if this approach works better than surgery alone at preventing the cancer from coming back within two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPOTACELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
RECRUITINGWuhan, Hubei, 438700, China
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.